End-of-day quote
Other stock markets
|
||
- USD | - |
03-28 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-05 | Top Midday Gainers | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 43 | 100.0 % | 34 | 100.0 % | -21.41% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 43 | 100.0 % | 34 | 100.0 % | -21.41% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 18-08-31 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 16-12-31 |
Chief Tech/Sci/R&D Officer | 65 | 17-03-31 | |
Wei Gao
LAW | General Counsel | 42 | 22-12-31 |
Kun Qian
AUD | Comptroller/Controller/Auditor | 42 | 21-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Yue Wu
BRD | Director/Board Member | 62 | 13-03-31 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 23-03-20 |
Thomas Folinsbee
BRD | Director/Board Member | 57 | 23-03-20 |
Xue Bo Zeng
BRD | Director/Board Member | 39 | 23-03-20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 13,813,327 | 7,042,899 ( 50.99 %) | 411,952 ( 2.982 %) | 50.99 % |
Company contact information
CASI Pharmaceuticals, Inc.
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road
100025, Beijing
+
http://www.casipharmaceuticals.comSector
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- CASI Stock
- Stock
- Company EntreMed Inc